| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials
|
Davids, Matthew S.
|
|
|
8 |
13 |
p. 3345-3359
|
artikel
|
| 2 |
A research center’s experience of T-cell–redirecting therapies in triple-class refractory multiple myeloma
|
Puertas, Borja
|
|
|
8 |
13 |
p. 3478-3487
|
artikel
|
| 3 |
ASH Guideline Oversight Subcommittee Response to Jacobs et al regarding Industry Payments to ASH Guideline Panelists
|
Pai, Menaka
|
|
|
8 |
13 |
p. 3553-3554
|
artikel
|
| 4 |
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status
|
Dolnikova, Alexandra
|
|
|
8 |
13 |
p. 3532-3543
|
artikel
|
| 5 |
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience
|
Ahmed, Gulrayz
|
|
|
8 |
13 |
p. 3528-3531
|
artikel
|
| 6 |
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy
|
Ledergor, Guy
|
|
|
8 |
13 |
p. 3562-3575
|
artikel
|
| 7 |
Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepository
|
Shannon, Morgan L.
|
|
|
8 |
13 |
p. 3453-3463
|
artikel
|
| 8 |
Clonal hematopoiesis of indeterminate potential in patients with immunoglobulin light-chain AL amyloidosis
|
Lopedote, Paolo
|
|
|
8 |
13 |
p. 3427-3436
|
artikel
|
| 9 |
Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma
|
Sharma, Sandhya
|
|
|
8 |
13 |
p. 3360-3371
|
artikel
|
| 10 |
Decision theoretical foundations of clinical practice guidelines: an extension of the ASH thrombophilia guidelines
|
Djulbegovic, Benjamin
|
|
|
8 |
13 |
p. 3596-3606
|
artikel
|
| 11 |
Defining primary refractory large B-cell lymphoma
|
Bock, Allison M.
|
|
|
8 |
13 |
p. 3402-3415
|
artikel
|
| 12 |
DISPLACE study shows poor quality of transcranial doppler ultrasound for stroke risk screening in sickle cell anemia
|
Davidow, Kimberly A.
|
|
|
8 |
13 |
p. 3444-3452
|
artikel
|
| 13 |
“Don't keep me waiting”: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes
|
Vadgama, Sachin
|
|
|
8 |
13 |
p. 3519-3527
|
artikel
|
| 14 |
Essential role of glycoprotein Ibα in platelet activation
|
Yan, Rong
|
|
|
8 |
13 |
p. 3388-3401
|
artikel
|
| 15 |
HLA reduction of human T cells facilitates generation of immunologically multicompatible cellular products
|
Winterhalter, Pascal M.
|
|
|
8 |
13 |
p. 3416-3426
|
artikel
|
| 16 |
Immune thrombocytopenia guidelines get an annual checkup
|
Gallo, Paul M.
|
|
|
8 |
13 |
p. 3576-3577
|
artikel
|
| 17 |
Industry payments to American Society of Hematology Clinical Practice Guideline authors
|
Jacobs, Jeremy W.
|
|
|
8 |
13 |
p. 3549-3552
|
artikel
|
| 18 |
Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis
|
Reynolds, Gemma K.
|
|
|
8 |
13 |
p. 3555-3559
|
artikel
|
| 19 |
Lysosomal degradation targets mutant calreticulin and the thrombopoietin receptor in myeloproliferative neoplasms
|
Kaur, Amanpreet
|
|
|
8 |
13 |
p. 3372-3387
|
artikel
|
| 20 |
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults
|
Lamble, Adam J.
|
|
|
8 |
13 |
p. 3544-3548
|
artikel
|
| 21 |
The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review
|
Ramachandran, Ramya
|
|
|
8 |
13 |
p. 3464-3467
|
artikel
|
| 22 |
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
|
Bhansali, Rahul S.
|
|
|
8 |
13 |
p. 3507-3518
|
artikel
|
| 23 |
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
|
DeFilipp, Zachariah
|
|
|
8 |
13 |
p. 3488-3496
|
artikel
|
| 24 |
The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia
|
Neunert, Cindy E.
|
|
|
8 |
13 |
p. 3578-3582
|
artikel
|
| 25 |
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
|
Patel, Anand A.
|
|
|
8 |
13 |
p. 3468-3477
|
artikel
|
| 26 |
Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities
|
Khera, Nandita
|
|
|
8 |
13 |
p. 3497-3506
|
artikel
|
| 27 |
Understanding CAR-T therapy in myeloma: 1 cell at a time
|
Dhodapkar, Madhav V.
|
|
|
8 |
13 |
p. 3560-3561
|
artikel
|
| 28 |
Unraveling facets of MECOM-associated syndrome: somatic genetic rescue, clonal hematopoiesis, and phenotype expansion
|
Venugopal, Parvathy
|
|
|
8 |
13 |
p. 3437-3443
|
artikel
|
| 29 |
Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?
|
Masetti, Riccardo
|
|
|
8 |
13 |
p. 3583-3595
|
artikel
|
Tijdschrift beschrijving